JP2024525815A - 新規のｔ細胞受容体を作製するための組成物および方法 - Google Patents

新規のｔ細胞受容体を作製するための組成物および方法 Download PDF

Info

Publication number
JP2024525815A
JP2024525815A JP2024502111A JP2024502111A JP2024525815A JP 2024525815 A JP2024525815 A JP 2024525815A JP 2024502111 A JP2024502111 A JP 2024502111A JP 2024502111 A JP2024502111 A JP 2024502111A JP 2024525815 A JP2024525815 A JP 2024525815A
Authority
JP
Japan
Prior art keywords
cells
antigen
cell
receptor
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525815A5 (enExample
Inventor
チェン，ビンビン
ファスト，イーサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vcreate Inc
Original Assignee
Vcreate Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vcreate Inc filed Critical Vcreate Inc
Publication of JP2024525815A publication Critical patent/JP2024525815A/ja
Publication of JP2024525815A5 publication Critical patent/JP2024525815A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024502111A 2021-07-15 2022-07-12 新規のｔ細胞受容体を作製するための組成物および方法 Pending JP2024525815A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163222130P 2021-07-15 2021-07-15
US63/222,130 2021-07-15
US202263300905P 2022-01-19 2022-01-19
US63/300,905 2022-01-19
US202263344221P 2022-05-20 2022-05-20
US63/344,221 2022-05-20
PCT/US2022/036841 WO2023287803A2 (en) 2021-07-15 2022-07-12 Compositions and methods for making novel t-cell receptors

Publications (2)

Publication Number Publication Date
JP2024525815A true JP2024525815A (ja) 2024-07-12
JP2024525815A5 JP2024525815A5 (enExample) 2025-06-16

Family

ID=84919648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502111A Pending JP2024525815A (ja) 2021-07-15 2022-07-12 新規のｔ細胞受容体を作製するための組成物および方法

Country Status (4)

Country Link
US (1) US12606936B2 (enExample)
EP (1) EP4370542A4 (enExample)
JP (1) JP2024525815A (enExample)
WO (1) WO2023287803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4281569A4 (en) * 2021-01-25 2025-04-02 The Regents Of The University Of California Methods and compositions for labeling and selecting antigen-specific T cells
IL325949A (en) * 2023-07-18 2026-03-01 Heligenics Inc Method for producing and screening multi-functional chimeric biologic libraries
WO2025032194A1 (en) * 2023-08-08 2025-02-13 Ospedale San Raffaele S.R.L. T-cell receptors
CN117338914B (zh) * 2023-10-27 2024-09-06 中山市珈钰生物医药有限公司 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用
WO2025160372A1 (en) * 2024-01-24 2025-07-31 Hifibio Sas Methods for identification of cognate pairs of ligands and receptors
WO2026043868A1 (en) * 2024-08-20 2026-02-26 Amgen Inc. A cell-based platform for identifying native protein-protein interactions in mammalian display libraries
WO2026040998A1 (zh) * 2024-08-20 2026-02-26 上海灵识质源生物技术有限公司 Tp53突变体表位肽和特异性t细胞受体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020125762A1 (en) * 2018-12-20 2020-06-25 Peking University Compositions and methods for highly efficient genetic screening using barcoded guide rna constructs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
AU2016326734B2 (en) * 2015-09-25 2022-07-07 Abvitro Llc High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
CN114127305A (zh) 2019-05-23 2022-03-01 麻省理工学院 经由逆转录病毒表面展示的配体发现和基因递送

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020125762A1 (en) * 2018-12-20 2020-06-25 Peking University Compositions and methods for highly efficient genetic screening using barcoded guide rna constructs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONNOR S. DOBSON ET AL.: ""Antigen identification and high-throughput interaction mapping by reprogramming viral entry"", NATURE METHODS, vol. 19, no. 4, JPN6026020420, April 2022 (2022-04-01), pages 449 - 460, ISSN: 0005869376 *
JUSTIN A. BOSCH ET AL.: ""Precise genome engineering in Drosophila using prime editing"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 118, no. 1, JPN6026020422, 21 December 2020 (2020-12-21), ISSN: 0005869377 *

Also Published As

Publication number Publication date
EP4370542A2 (en) 2024-05-22
WO2023287803A3 (en) 2023-05-04
US20230071148A1 (en) 2023-03-09
WO2023287803A2 (en) 2023-01-19
EP4370542A4 (en) 2025-09-17
US12606936B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
US12606936B2 (en) Compositions and methods for making novel T-cell receptors
US20240084253A1 (en) Method of assessing activity of recombinant antigen receptors
JP2019536437A (ja) Ｈｐｖ特異的結合分子
WO2017064084A1 (en) Novel chimeric antigen receptors
CN109153975A (zh) 制备嵌合抗原受体表达细胞的方法
JP2022538148A (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
CN110511912A (zh) 免疫细胞的功能调节
WO2021030182A1 (en) Bifunctional single variable domain t cell receptors and uses thereof
TW202317602A (zh) 嵌合多肽
KR20210138043A (ko) 고 결합 활성 wt1 t 세포 수용체 및 이의 용도
CN115427550A (zh) T细胞转导方法
WO2023207390A1 (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
Jorritsma et al. Prospects and limitations of T cell receptor gene therapy
CN114555790B (zh) Wt-1特异性t细胞免疫疗法
CN113286815B (zh) 间皮素特异性t细胞受体及其在免疫治疗中的应用
KR20260016919A (ko) 제시된 hpv16-, mart1-, cmv-, ebv-, 또는 인플루엔자-펩티드에 결합하는 t 세포 수용체
EP4534554A1 (en) Mage-a1 specific tcr and use thereof
WO2024254775A1 (zh) 包含新型共刺激结构域的嵌合抗原受体及其用途
WO2023213969A1 (en) Viral-binding protein and related reagents, articles, and methods of use
CN117751135A (zh) 制造新颖t细胞受体的组合物和方法
US20230133564A1 (en) Cd3-fusion protein and uses thereof
US20250235477A1 (en) Method for targeted gene insertion into immune cells
US20250257337A1 (en) Augmenting car t cell activity
EP4737476A1 (en) T-cell receptor variant against mkras 7-16 g12d

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526